Carl Bjartmar appointed as new Chief Medical Officer for Ascelia Pharma


Ascelia Pharma announces today that Carl Bjartmar, MD, PhD, has been appointed as new Chief Medical Officer (CMO) for Ascelia Pharma. Carl has most recently worked as CMO for Wilson Therapeutics.

Carl brings substantial experience in late-stage drug development in orphan diseases having served in senior roles in both large international pharma companies such as Sanofi, Genzyme and Lundbeck as well as in the Swedish biotech company Wilson Therapeutics as CMO. Carl is a Medical Doctor (M.D.) and holds a PhD degree from University of Linköping.

“We are very pleased with the appointment of Carl Bjartmar as CMO. Carl has a long and solid track record in late-stage orphan drug development and has among other things been a key member of the management team in Wilson Therapeutics with important achievements including its IPO on Nasdaq OMX in 2016, planning and execution of phase 3 development and the acquisition of Wilson Therapeutics by Alexion Pharmaceuticals in 2018. This is of particular importance to Ascelia’s lead drug candidate Mangoral® that has obtained Orphan Drug Designation from the FDA and is currently being prepared for its phase 3 clinical development”, says Magnus Corfitzen, Chief Executive Officer of Ascelia Pharma.

“I look forward to joining Ascelia Pharma and to contribute in its mission to improve the lives of patients living with cancer. Ascelia has two promising drug candidates, one in late-stage clinical development (Mangoral®) and one in earlier stage (Oncoral) and I’m strongly motivated to advance the development of these and bring them to patients”, says Carl Bjartmar.

For further information contact:
Magnus Corfitzen, CEO, +46 735 179 110

About Ascelia Pharma

Ascelia Pharma is a specialty pharmaceutical company dedicated to the development of novel medicines to improve the life expectancy and quality of life for people living with cancer. The company is located at Medeon Science Park in Malmö, Sweden in the middle of Medicon Valley, a leading European life science cluster. For more information, please visit


Information regarding transfer of shares in Ascelia Pharma AB from CMC SPV

Ascelia Pharma AB (publ) (ticker: ACE) (“Ascelia Pharma” or the “Company”) today announced that it has been informed of that CMC SPV of 3 April 2017 AB (“CMC SPV”) today has divested 687,606 shares in the Company in a private placement to institutional investors and distributed 2,250,000 shares in the Company to its shareholders, including Sunstone and certain members of the board of directors and management of Ascelia Pharma. Followi ...

Ascelia Pharma presents clinical development plan for Oncoral as a novel chemotherapy

Ascelia Pharma AB (publ) (ticker: ACE) today announced the clinical development plan for Oncoral. With Oncoral, Ascelia Pharma has the opportunity to develop a novel oral chemotherapy with the potential to offer both efficacy and safety benefits to cancer patients. The planned Phase 2 study, for the treatment of gastric cancer, is expected to start in H2 2021. Further details of the Oncoral development plan can be found on its dedicated website.

Ascelia Pharma gets US patent for second generation Mangoral

Ascelia Pharma AB (publ) (ticker: ACE) today announced that the US Patent Office (USPTO) has issued a new patent covering a second-generation formulation of lead drug candidate Mangoral, currently in the pivotal Phase 3 study SPARKLE. The new patent further improves the unique value proposition of the Mangoral franchise and provides patent protection until year 2040 in the US.